In 2017,Walker, Ann L.; Ancellin, Nicolas; Beaufils, Benjamin; Bergeal, Marylise; Binnie, Margaret; Clapham, David; Haslam, Carl P.; Holmes, Duncan S.; Hutchinson, Jonathan P.; Liddle, John; McBride, Andrew; Mirguet, Olivier; Mowat, Christopher G.; Rowland, Paul; Tiberghien, Nathalie; Trottet, Lionel; Uings, Iain; Webster, Scott P.; Zheng, Xiaozhong; Mole, Damian J. published 《Development of a Series of Kynurenine 3-Monooxygenase Inhibitors Leading to a Clinical Candidate for the Treatment of Acute Pancreatitis》.Journal of Medicinal Chemistry published the findings.Application of 3395-91-3 The information in the text is summarized as follows:
Recently, we reported a novel role for KMO in the pathogenesis of acute pancreatitis (AP). A number of inhibitors of kynurenine 3-monooxygenase (KMO) have previously been described as potential treatments for neurodegenerative conditions and particularly for Huntington’s disease. However the inhibitors reported to date have insufficient aqueous solubility relative to their cellular potency to be compatible with the i.v. (i.v.) dosing route required in AP. We have identified and optimized a novel series of high affinity KMO inhibitors with favorable physicochem. properties. The leading example is exquisitely selective, has low clearance in two species, prevents lung and kidney damage in a rat model of acute pancreatitis and is progressing into preclin. development. In the experimental materials used by the author, we found Methyl 3-bromopropanoate(cas: 3395-91-3Application of 3395-91-3)
Methyl 3-bromopropanoate(cas: 3395-91-3) belongs to bromides. Most organobromine compounds, like most organohalide compounds, are relatively nonpolar. Bromine is more electronegative than carbon (2.9 vs 2.5). Consequently, the carbon in a carbon–bromine bond is electrophilic, i.e. alkyl bromides are alkylating agents.Application of 3395-91-3
Referemce:
Bromide – Wikipedia,
bromide – Wiktionary